Literature DB >> 19822219

The effect of the composition of unrelated donor bone marrow and peripheral blood progenitor cell grafts on transplantation outcomes.

Nancy H Collins1, Adrian P Gee, April G Durett, Fangyu Kan, Mei-Jie Zhang, Richard E Champlin, Dennis Confer, Mary Eapen, Alan Howard, Roberta King, Mary J Laughlin, Robert J Plante, Michelle Setterholm, Stephen Spellman, Carolyn Keever-Taylor, John E Wagner, Daniel J Weisdorf.   

Abstract

To test the hypothesis that the outcome of hematopoietic stem cell (HSC) grafts is at least partially determined by the cellular composition of the graft, the National Marrow Donor Program (NMDP) analyzed the correlation of cellular phenotypes of unrelated grafts with graft outcome. Samples from 94 bone marrow (BM) and 181 peripheral blood progenitor cell (PBPC) grafts for transplantations at 40 U.S. transplant centers between 2003 and 2005 were analyzed at a single immunophenotyping reference laboratory. Samples were shipped from transplant centers upon receipt of graft. Graft cellular composition included analysis of leukocyte total cell numbers, and subsets of myeloid [CD34(+), CD34(+) CD38(-)], lymphoid [CD3(+), CD3(+) CD4(+), CD3(+) CD8(+)], and activated lymphoid cells [CD3(+) CD25(+), CD3(+) CD69(+), CD3(+) HLA-DR(+)] coexpressing CD3(+). There was substantial variability in the cellular composition of BM and PBPC grafts before and after graft processing by red blood cell (RBC) removal or plasma depletion in preparation for transplant. With BM grafts, cellular composition was not associated with hematopoietic recovery, graft-versus-host disease (GVHD), or survival. With PBPC grafts, survival rates were higher with CD34(+)>5 x 10(6)/kg, 59% compared to 34% with CD34(+)< or =5 x 10(6)/kg at 1 year. Platelet recovery was higher with PBPC containing CD3(+) CD8(+) >8 x 10(7)/kg. Neutrophil recovery or GVHD could not be predicted by any cellular subsets of PBPC grafts. Although survival was superior with PBPC grafts containing >5 x 10(6) CD34(+)/kg, an optimal graft mix of myeloid, lymphoid, and activated lymphoid subsets was not identified. Copyright 2010 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19822219      PMCID: PMC2952392          DOI: 10.1016/j.bbmt.2009.10.004

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  21 in total

Review 1.  Estimation of failure probabilities in the presence of competing risks: new representations of old estimators.

Authors:  T A Gooley; W Leisenring; J Crowley; B E Storer
Journal:  Stat Med       Date:  1999-03-30       Impact factor: 2.373

2.  Allogeneic blood and bone-marrow stem-cell transplantation in haematological malignant diseases: a randomised trial.

Authors:  R Powles; J Mehta; S Kulkarni; J Treleaven; B Millar; J Marsden; V Shepherd; A Rowland; B Sirohi; D Tait; C Horton; S Long; S Singhal
Journal:  Lancet       Date:  2000-04-08       Impact factor: 79.321

3.  High doses of transplanted CD34+ cells are associated with rapid T-cell engraftment and lessened risk of graft rejection, but not more graft-versus-host disease after nonmyeloablative conditioning and unrelated hematopoietic cell transplantation.

Authors:  F Baron; M B Maris; B E Storer; B M Sandmaier; J P Panse; T R Chauncey; M Sorror; M-T Little; D G Maloney; R Storb; S Heimfeld
Journal:  Leukemia       Date:  2005-05       Impact factor: 11.528

4.  CD34, CD4, and CD8 cell doses do not influence engraftment, graft-versus-host disease, or survival following myeloablative human leukocyte antigen-identical peripheral blood allografting for hematologic malignancies.

Authors:  Thai M Cao; Ruby M Wong; Kevin Sheehan; Ginna G Laport; Keith E Stockerl-Goldstein; Laura J Johnston; Judith A Shizuru; Robert S Negrin; Robert Lowsky
Journal:  Exp Hematol       Date:  2005-03       Impact factor: 3.084

5.  Unrelated donor marrow transplantation for acute myeloid leukemia: an update of the Seattle experience.

Authors:  J Sierra; B Storer; J A Hansen; P J Martin; E W Petersdorf; A Woolfrey; D Matthews; J E Sanders; R Storb; F R Appelbaum; C Anasetti
Journal:  Bone Marrow Transplant       Date:  2000-08       Impact factor: 5.483

6.  A randomised study of allogeneic transplantation with stem cells from blood or bone marrow.

Authors:  D Heldal; G Tjønnfjord; L Brinch; D Albrechtsen; T Egeland; R Steen; B G Solheim; S A Evensen
Journal:  Bone Marrow Transplant       Date:  2000-06       Impact factor: 5.483

7.  Peripheral blood vs bone marrow as a source for allogeneic hematopoietic stem cell transplantation.

Authors:  H Mahmoud; O Fahmy; A Kamel; M Kamel; A El-Haddad; D El-Kadi
Journal:  Bone Marrow Transplant       Date:  1999-08       Impact factor: 5.483

8.  Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers.

Authors:  W I Bensinger; P J Martin; B Storer; R Clift; S J Forman; R Negrin; A Kashyap; M E Flowers; K Lilleby; T R Chauncey; R Storb; F R Appelbaum
Journal:  N Engl J Med       Date:  2001-01-18       Impact factor: 91.245

9.  Analysis of risk factors for the development of GVHD after T cell-depleted allogeneic BMT: effect of HLA disparity, ABO incompatibility, and method of T-cell depletion.

Authors:  C A Keever-Taylor; C Bredeson; F R Loberiza; J T Casper; C Lawton; D Rizzo; W H Burns; D A Margolis; D H Vesole; M Horowitz; M J Zhang; M Juckett; W R Drobyski
Journal:  Biol Blood Marrow Transplant       Date:  2001       Impact factor: 5.742

10.  Classification of HLA-matching for retrospective analysis of unrelated donor transplantation: revised definitions to predict survival.

Authors:  Daniel Weisdorf; Stephen Spellman; Michael Haagenson; Mary Horowitz; Stephanie Lee; Claudio Anasetti; Michelle Setterholm; Rebecca Drexler; Martin Maiers; Roberta King; Dennis Confer; John Klein
Journal:  Biol Blood Marrow Transplant       Date:  2008-07       Impact factor: 5.742

View more
  11 in total

1.  Higher Donor Apheresis Blood Volumes Are Associated with Reduced Relapse Risk and Improved Survival in Reduced-Intensity Allogeneic Transplantations with Unrelated Donors.

Authors:  Lisa M Crisalli; Joanne T Hinkle; Christopher C Walling; Mary Sell; Noelle V Frey; Elizabeth O Hexner; Alison W Loren; Selina M Luger; Edward A Stadtmauer; David L Porter; Ran Reshef
Journal:  Biol Blood Marrow Transplant       Date:  2018-02-02       Impact factor: 5.742

2.  External validation of models for KIR2DS1/KIR3DL1-informed selection of hematopoietic cell donors fails.

Authors:  Johannes Schetelig; Henning Baldauf; Falk Heidenreich; Carolin Massalski; Sandra Frank; Jürgen Sauter; Matthias Stelljes; Francis Ayuketang Ayuk; Wolfgang A Bethge; Gesine Bug; Stefan Klein; Sarah Wendler; Vinzenz Lange; Liesbeth C de Wreede; Daniel Fürst; Guido Kobbe; Hellmut D Ottinger; Dietrich W Beelen; Joannis Mytilineos; Katharina Fleischhauer; Alexander H Schmidt; Martin Bornhäuser
Journal:  Blood       Date:  2020-04-16       Impact factor: 22.113

3.  Engineering human peripheral blood stem cell grafts that are depleted of naïve T cells and retain functional pathogen-specific memory T cells.

Authors:  Marie Bleakley; Shelly Heimfeld; Lori A Jones; Cameron Turtle; Diane Krause; Stanley R Riddell; Warren Shlomchik
Journal:  Biol Blood Marrow Transplant       Date:  2014-02-11       Impact factor: 5.742

4.  Outcomes of acute leukemia patients transplanted with naive T cell-depleted stem cell grafts.

Authors:  Marie Bleakley; Shelly Heimfeld; Keith R Loeb; Lori A Jones; Colette Chaney; Stuart Seropian; Ted A Gooley; Franziska Sommermeyer; Stanley R Riddell; Warren D Shlomchik
Journal:  J Clin Invest       Date:  2015-06-08       Impact factor: 14.808

5.  The effect of donor characteristics on survival after unrelated donor transplantation for hematologic malignancy.

Authors:  Craig Kollman; Stephen R Spellman; Mei-Jie Zhang; Anna Hassebroek; Claudio Anasetti; Joseph H Antin; Richard E Champlin; Dennis L Confer; John F DiPersio; Marcelo Fernandez-Viña; Robert J Hartzman; Mary M Horowitz; Carolyn K Hurley; Chatchada Karanes; Martin Maiers; Carlheinz R Mueller; Miguel-Angel Perales; Michelle Setterholm; Ann E Woolfrey; Neng Yu; Mary Eapen
Journal:  Blood       Date:  2015-11-02       Impact factor: 22.113

6.  Infused total nucleated cell dose is a better predictor of transplant outcomes than CD34+ cell number in reduced-intensity mobilized peripheral blood allogeneic hematopoietic cell transplantation.

Authors:  Paul S Martin; Shuli Li; Sarah Nikiforow; Edwin P Alyea; Joseph H Antin; Philippe Armand; Corey S Cutler; Vincent T Ho; Natasha Kekre; John Koreth; C John Luckey; Jerome Ritz; Robert J Soiffer
Journal:  Haematologica       Date:  2016-01-14       Impact factor: 9.941

7.  Prospective observational study on the first 51 cases of peripheral blood stem cell transplantation from unrelated donors in Japan.

Authors:  Tatsunori Goto; Takashi Tanaka; Masashi Sawa; Yasunori Ueda; Hiroatsu Ago; Shigeru Chiba; Heiwa Kanamori; Akinori Nishikawa; Masaharu Nougawa; Kazuteru Ohashi; Hirokazu Okumura; Mitsune Tanimoto; Takahiro Fukuda; Naomi Kawashima; Tomonori Kato; Kazuya Okada; Koji Nagafuji; Shin-Ichiro Okamoto; Yoshiko Atsuta; Masayuki Hino; Junji Tanaka; Koichi Miyamura
Journal:  Int J Hematol       Date:  2017-10-13       Impact factor: 2.490

8.  Fractionated Infusion of Hematopoietic Progenitor Cells Does Not Improve Neutrophil Recovery or Survival in Allograft Recipients.

Authors:  Roni Tamari; Samantha Brown; Sean M Devlin; Satyajit Kosuri; Molly A Maloy; Doris M Ponce; Craig Sauter; Brian Shaffer; Parastoo Dahi; James W Young; Ann Jakubowski; Esperanza B Papadopoulos; Hugo Castro-Malaspina; Miguel-Angel Perales; Sergio A Giralt; Boglarka Gyurkocza
Journal:  Transplant Cell Ther       Date:  2021-06-30

9.  Prospective cohort study of the circadian rhythm pattern in allogeneic sibling donors undergoing standard granulocyte colony-stimulating factor mobilization.

Authors:  Patricia A Shi; Luis M Isola; Janice L Gabrilove; Erin L Moshier; James H Godbold; Lorraine K Miller; Paul S Frenette
Journal:  Stem Cell Res Ther       Date:  2013-03-20       Impact factor: 6.832

10.  Impact of clinical factors and allograft leukocyte content on post-transplant lymphopenia, monocytopenia, and survival in patients undergoing allogeneic peripheral blood haematopoietic cell transplant.

Authors:  Mary D Thoma; Jennifer Glejf; Eapen Jacob; Tanya J Huneke; Lori J DeCook; Nicci D Johnson; Mrinal M Patnaik; Mark R Litzow; William J Hogan; Laura F Newell; Rekha Chandran; Luis F Porrata; Shernan G Holtan
Journal:  BMC Hematol       Date:  2014-09-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.